Temoporfin
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.152.970
Chemical and physical data
FormulaC44H32N4O4
Molar mass680.764 g·mol−1
3D model (JSmol)
  • C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O
  • InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-
  • Key:LYPFDBRUNKHDGX-LWQDQPMZSA-N
  (verify)

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck[1] .[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.[3]

Good results were obtained in 21 of 35 patients treated in Germany.[4]

It is photoactivated at 652 nm[2] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.[2]

References

  1. Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". Hno (in German). 56 (4): 402–409. doi:10.1007/s00106-007-1573-1. PMID 17516041.
  2. 1 2 3 O'Connor AE, Gallagher WM, Byrne AT (2009). "Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy". Photochemistry and Photobiology. 85 (5): 1053–1074. doi:10.1111/j.1751-1097.2009.00585.x. PMID 19682322. S2CID 205950773.
  3. "Foscan approval saves Scotia's skin". HighBeam. Archived from the original on 2012-11-04.
  4. Lorenz KJ, Maier H (December 2009). "Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients". European Archives of Oto-Rhino-Laryngology. 266 (12): 1937–1944. doi:10.1007/s00405-009-0947-2. PMID 19290535. S2CID 5892034.

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.